The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Tramadol for neuropathic pain in adults
Open accessAbstract
BACKGROUND: This review is an update of a review of tramadol for neuropathic pain, published in 2006; updating was to bring the review in line with current standards. Neuropathic pain, which is caused by a lesion or disease affecting the somatosensory system, may be central or peripheral in origin. Peripheral neuropathic pain often includes symptoms such as burning or shooting sensations, abnormal sensitivity to normally painless stimuli, or an increased sensitivity to normally painful stimuli. Neuropathic pain is a common symptom in many diseases of the peripheral nervous system. OBJECTIVES: To assess the analgesic efficacy of tramadol compared with placebo or other active interventions for chronic neuropathic pain in adults, and the adverse events associated with its use in clinical trials. SEARCH METHODS: We searched CENTRAL, MEDLINE, and Embase for randomised controlled trials from inception to January 2017. We also searched the reference lists of retrieved studies and reviews, and online clinical trial registries. SELECTION CRITERIA: We included randomised, double-blind trials of two weeks' duration or longer, comparing tramadol (any route of administration) with placebo or another active treatment for neuropathic pain, with subjective pain assessment by the participant. DATA COLLECTION AND ANALYSIS: Two review authors independently extracted data and assessed trial quality and potential bias. Primary outcomes were participants with substantial pain relief (at least 50% pain relief over baseline or very much improved on Patient Global Impression of Change scale (PGIC)), or moderate pain relief (at least 30% pain relief over baseline or much or very much improved on PGIC). Where pooled analysis was possible, we used dichotomous data to calculate risk ratio (RR) and number needed to treat for an additional beneficial outcome (NNT) or harmful outcome (NNH), using standard methods. We assessed the quality of the evidence using GRADE and created 'Summary of findings' tables. MAIN RESULTS: We identified six randomised, double-blind studies involving 438 participants with suitably characterised neuropathic pain. In each, tramadol was started at a dose of about 100 mg daily and increased over one to two weeks to a maximum of 400 mg daily or the maximum tolerated dose, and then maintained for the remainder of the study. Participants had experienced moderate or severe neuropathic pain for at least three months due to cancer, cancer treatment, postherpetic neuralgia, peripheral diabetic neuropathy, spinal cord injury, or polyneuropathy. The mean age was 50 to 67 years with approximately equal numbers of men and women. Exclusions were typically people with other significant comorbidity or pain from other causes. Study duration for treatments was four to six weeks, and two studies had a cross-over design.Not all studies reported all the outcomes of interest, and there were limited data for pain outcomes. At least 50% pain intensity reduction was reported in three studies (265 participants, 110 events). Using a random-effects analysis, 70/132 (53%) had at least 50% pain relief with tramadol, and 40/133 (30%) with placebo; the risk ratio (RR) was 2.2 (95% confidence interval (CI) 1.02 to 4.6). The NNT calculated from these data was 4.4 (95% CI 2.9 to 8.8). We downgraded the evidence for this outcome by two levels to low quality because of the small size of studies and of the pooled data set, because there were only 110 actual events, the analysis included different types of neuropathic pain, the studies all had at least one high risk of potential bias, and because of the limited duration of the studies.Participants experienced more adverse events with tramadol than placebo. Report of any adverse event was higher with tramadol (58%) than placebo (34%) (4 studies, 266 participants, 123 events; RR 1.6 (95% CI 1.2 to 2.1); NNH 4.2 (95% CI 2.8 to 8.3)). Adverse event withdrawal was higher with tramadol (16%) than placebo (3%) (6 studies, 485 participants, 45 events; RR 4.1 (95% CI 2.0 to 8.4); NNH 8.2 (95% CI 5.8 to 14)). Only four serious adverse events were reported, without obvious attribution to treatment, and no deaths were reported. We downgraded the evidence for this outcome by two or three levels to low or very low quality because of small study size, because there were few actual events, and because of the limited duration of the studies. AUTHORS' CONCLUSIONS: There is only modest information about the use of tramadol in neuropathic pain, coming from small, largely inadequate studies with potential risk of bias. That bias would normally increase the apparent benefits of tramadol. The evidence of benefit from tramadol was of low or very low quality, meaning that it does not provide a reliable indication of the likely effect, and the likelihood is very high that the effect will be substantially different from the estimate in this systematic review.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., Gilron, I., Haanpää, M., Hansson, P., Jensen, T. S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70251-0 · Cited by 3,980
Self-citationDworkin, R. H., Turk, D. C., Wyrwich, K. W., Beaton, D., Cleeland, C. S., Farrar, J. T., Haythornthwaite, J. A., Jensen, M. P., Kerns, R. D., Ader, D. N., et al. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.09.005 · Cited by 3,471
Meta-Analysis in Clinical Research
L'ABBÉ, K. A., DETSKY, A. S., & O'ROURKE, K. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-224 · Cited by 1,267
GRADE guidelines: 12. Preparing Summary of Findings tables—binary outcomes
Guyatt, G. H., Oxman, A. D., Santesso, N., Helfand, M., Vist, G., Kunz, R., Brozek, J., Norris, S., Meerpohl, J., Djulbegovic, B., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.01.012 · Cited by 836
Guyatt, G., Oxman, A. D., Sultan, S., Brozek, J., Glasziou, P., Alonso-Coello, P., Atkins, D., Kunz, R., Montori, V., Jaeschke, R., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.01.006 · Cited by 762
The impact of study size on meta-analyses: examination of underpowered studies in Cochrane reviews
Turner, R. M., Bird, S. M., & Higgins, J. P. T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059202 · Cited by 672
Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia
Lunn, M. P., Hughes, R. A., & Wiffen, P. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007115.pub3 · Cited by 565
Self-citationSmall study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study
Nuesch, E., Trelle, S., Reichenbach, S., Rutjes, A. W. S., Tschannen, B., Altman, D. G., Egger, M., & Juni, P. (2010) · BMJ · doi:10.1136/bmj.c3515 · Cited by 559
Influence of trial sample size on treatment effect estimates: meta-epidemiological study
Dechartres, A., Trinquart, L., Boutron, I., & Ravaud, P. (2013) · BMJ · doi:10.1136/bmj.f2304 · Cited by 544
Cited by
Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy
Sloan, G., Selvarajah, D., & Tesfaye, S. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00496-z · Cited by 534
Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy
Iqbal, Z., Azmi, S., Yadav, R., Ferdousi, M., Kumar, M., Cuthbertson, D. J., Lim, J., Malik, R. A., & Alam, U. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.04.001 · Cited by 487
“9),(149) it still concluded that there were insufficient data of adequate quality to provide convincing evidence that tramadol is effective in relieving neuropathic pain.(149) Anecdotally, tramadol may be used to treat breakthrough pain in combination with other neuropathic pain agents, although its use in combination…”
BackgroundInfluentialChallenges of neuropathic pain: focus on diabetic neuropathy
Rosenberger, D. C., Blechschmidt, V., Timmerman, H., Wolff, A., & Treede, R.-D. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-020-02145-7 · Cited by 325
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
Treating pain in diabetic neuropathy: current and developmental drugs
Alam, U., Sloan, G., & Tesfaye, S. (2020) · Drugs · doi:10.1007/s40265-020-01259-2 · Cited by 104
Metadata
- Authors
- Duehmke, R. M., Derry, S., Wiffen, P. J., Bell, R. F., Aldington, D., & Moore, R. A.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2017-06-15
- Volume
- 2017
- Issue
- 6
- Pages
- CD003726-CD003726
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2625683325
- Cited by
- 191
- References
- 14
- FWCI
- 11.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tramadol for neuropathic pain in adults. https://app.cochat.ai/papers/10.1002/14651858.cd003726.pub4
- The paper
- Duehmke, R. M., Derry, S., Wiffen, P. J., Bell, R. F., Aldington, D., & Moore, R. A. (2017). Tramadol for neuropathic pain in adults. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd003726.pub4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.